Austria’s HEROSAN Opens €1.5 Million Bond Crowdfunding on Invesdor to Scale Insect-Based Hypoallergenic Dog Food Across Europe
Executive Summary: HEROSAN Petcare GmbH, an Austrian pet nutrition company majority-owned by REPLOID Group, opened a crowdfunding campaign on September 8, 2026, seeking up to €1.5 million through corporate bonds on the Invesdor platform. The bonds pay a fixed 9.0% annual interest over five years, with a minimum ticket of €250. HEROSAN builds dog and cat diets on insect protein and mushroom-derived ingredients for animals with allergies and food intolerances, and reported first-half 2026 revenue of €2.3 million, up 64% year-over-year.
Key Facts
- Company
- HEROSAN Petcare GmbH (Styria, Austria), part of REPLOID Group
- Event
- Crowdfunding bond campaign opened on Invesdor
- Date
- September 8, 2026
- Size
- Up to €1,500,000; minimum investment €250
- Terms
- 9.0% fixed annual interest, five-year term, semi-annual installments
- Use of Proceeds
- Product development, marketing, e-commerce expansion
- Revenue
- €2.3 million in H1 2026, +64% year-over-year
- Source
- REPLOID Group AG press release via EQS News
What Happened
HEROSAN Petcare GmbH opened its crowdfunding campaign on the Invesdor platform on September 8, 2026, offering corporate bonds rather than equity. The issue is capped at €1.5 million, carries a fixed 9.0% annual coupon over five years with interest and principal repaid in semi-annual installments, and starts at €250 per bond. The company, headquartered in southern Styria and majority-owned by Vienna-listed insect-farming group REPLOID, said proceeds will fund product development, marketing and e-commerce expansion, with co-founder Daniel Taurer specifically pointing to internationalization, web-shop and ERP investment. Bondholders get tiered discounts in the HEROSAN online shop — 15% from one bond, 20% from ten, 30% from 28 — valid through March 31, 2027.
Background: A REPLOID Group Portfolio Bet on Alternative Protein
HEROSAN was founded in 2019 and sells complete pet foods built on insect protein under the entoVITAL brand — described by its parent as Austria’s first insect-based pet nutrition range — plus fungoVITAL, a concept that combines fermentation-based bacterial protein with medicinal mushrooms and fungal mycelium, and TAMACAN, a line of EU-wide approved veterinary preparations based on full-spectrum CBD extract. The company’s recipes are developed with veterinarians for pets with allergies and intolerances. Capital and raw materials now come from inside the group: REPLOID raised its stake from 34% to more than 50% at the end of June 2026, Salzburg supplement group BIOGENA took 13.7%, and the founders hold the remaining 33% through PT26 Holding. REPLOID supplies black soldier fly larvae from its modular ReFarmUnits and mushroom mycelium from its subsidiary Vitus, which gives HEROSAN a vertically linked supply chain most alternative-protein pet food brands do not have. Since REPLOID’s initial investment in fall 2025, revenue grew 64% to €2.3 million in the first half of 2026, and sales activity expanded into Switzerland and Italy.
Industry Context: Where Insect Protein Fits in the Hypoallergenic Dog Food Aisle
HEROSAN is positioning into the most contested shelf in premium pet food. Owners triaging an itchy or food-reactive dog usually work through a familiar sequence — grain free dog food, then limited ingredient dog food recipes, then prescription hydrolyzed diets — even though true grain allergy is uncommon and most canine food reactions involve animal proteins the dog has seen repeatedly, such as beef or chicken. That is the gap insect protein attacks: larvae-derived meal is a protein source most dogs have never encountered, so it functions as a genuine novel protein rather than a carbohydrate-avoidance strategy. The category is small but compounding. Future Market Insights valued the global insect-protein pet food market at $142.6 million in 2025 and projects $614.8 million by 2036. Regulatory groundwork is in place — AAFCO authorized yellow mealworm protein for canine use in the US in 2024, and EU novel-food approvals for insect meal in pet food predate that. What has been missing is industrial supply and retail price points, which is precisely what a vertically integrated parent like REPLOID is built to fix.
Market & Business Impact
The bond structure tells you where the company is: revenue is real (€2.3 million in H1 2026) but small, so equity terms would have been punishing and debt at 9% is cheaper than a down-round. For bond investors the return depends on HEROSAN scaling distribution through vet and veterinary-naturopath channels, its historic route to market, plus the newer Swiss and Italian pushes. For the wider industry, the campaign is a template other mid-size alternative-protein makers will study: retail-adjacent crowdfunding with shop discounts converts customers into lenders and locks in loyalty at the same time. Distributors and manufacturers watching the allergy segment should note the group structure too — when insect larvae, mushroom mycelium and the pet food brand sit inside one group, margin stacks differently than in the asset-light brands that license ingredients from third-party farms.
Companies & Brands Involved
HEROSAN Petcare GmbH — issuer, Styria, founded 2019; brands entoVITAL (insect-based dog and cat food), fungoVITAL (fermentation protein + medicinal mushrooms), TAMACAN (CBD veterinary preparations). REPLOID Group AG — Vienna Stock Exchange direct market plus (HRX5), more than 190 employees, supplies larvae and mycelium and holds the majority stake. BIOGENA — Salzburg supplement group, 13.7% stake, active in animal health through BIOGENA PETS. PT26 Holding GmbH — founders Cornelia Pint and Daniel Taurer, 33%. Invesdor — crowdfunding platform hosting the bond issue.
Data & Evidence
Issue size: up to €1,500,000. Coupon: 9.0% fixed annual, five-year term, semi-annual installments. Minimum ticket: €250. Revenue: €2.3 million in H1 2026, up 64% year-over-year (company figures via EQS press release). Ownership: REPLOID more than 50% (raised from 34% end of June 2026), BIOGENA 13.7%, PT26 Holding 33%. Category sizing: global insect-protein pet food $142.6 million in 2025, projected $614.8 million by 2036 (Future Market Insights, via StartUp Beat). Customer rating cited by the company: 4.8 stars. Shop-discount ladder for bondholders: 15% / 20% / 30%, valid through March 31, 2027.
What This Means for the Pet Industry
GPI’s take: the interesting part of this deal is not the €1.5 million — it is who is lending and what they get. A 9% coupon plus shop discounts means HEROSAN is financing growth with its own customers and its own supply chain’s parent group standing behind it, which suits a niche brand whose buyers are unusually engaged. The strategic read for manufacturers is that alternative-protein pet food is consolidating vertically: whoever controls larvae, mycelium and the brand captures the whole margin, and everyone else becomes a contract filler. For pet owners, the practical question is whether novel-protein diets earn a place in the vet-recommended toolkit — the honest answer is that the evidence base is growing but thinner than for hydrolyzed prescription diets, and any owner of an allergic dog should run a diet trial with their veterinarian rather than self-prescribing. HEROSAN’s 64% growth says the demand is already there.
Key Takeaways
- HEROSAN Petcare GmbH opened a bond crowdfunding campaign on Invesdor on September 8, 2026, seeking up to €1.5 million at a fixed 9.0% annual rate over five years.
- The Austrian company builds pet diets on insect protein and mushroom-derived ingredients, aimed at animals with allergies and food intolerances.
- First-half 2026 revenue reached €2.3 million, up 64% year-over-year, since parent group REPLOID’s initial investment in fall 2025.
- REPLOID raised its stake above 50% at the end of June 2026 and supplies larvae and mushroom mycelium from its own group companies.
- The global insect-protein pet food market was valued at $142.6 million in 2025 and is projected to reach $614.8 million by 2036, according to Future Market Insights.
Frequently Asked Questions
What is HEROSAN raising and on what terms?
Up to €1.5 million through corporate bonds on the Invesdor platform, opened September 8, 2026. The bonds pay a fixed 9.0% annual interest over five years with semi-annual installments, and the minimum investment is €250. Proceeds fund product development, marketing and e-commerce.
Is insect-based food a realistic option as dog food for allergies?
It can be. Most canine food reactions target proteins a dog has eaten repeatedly, usually beef, chicken, dairy or wheat — so a protein source the dog has never encountered, such as black soldier fly larvae meal, can serve as a novel-protein trial diet. Insect digestibility trials in dogs have shown protein digestibility comparable to chicken- and beef-based diets. Owners of an allergic dog should still run a structured elimination trial with their veterinarian; insect-based hypoallergenic dog food is one tool in that process, not a guaranteed fix.
How is this different from grain-free or limited-ingredient diets?
Grain free dog food removes grains, and limited ingredient dog food shortens the recipe to a small set of components — but both usually keep conventional animal proteins as the base. True grain allergy in dogs is uncommon, so an insect-protein diet attacks the problem differently: it replaces the protein itself rather than the carbohydrate source. The two approaches can overlap — a grain-free insect recipe is possible — but the allergy logic is novel protein first.
What products does HEROSAN sell?
entoVITAL, an insect-protein complete food range for dogs and cats; fungoVITAL, which pairs fermentation-based bacterial protein with medicinal mushrooms and mycelium and is positioned for owners comparing options in dog food for sensitive stomach cases; and TAMACAN, EU-wide approved veterinary preparations based on full-spectrum CBD extract. Distribution runs primarily through vets and veterinary naturopaths, with expanding e-commerce in Austria, Switzerland and Italy.
Who owns HEROSAN?
REPLOID Group AG holds more than 50% after increasing from 34% at the end of June 2026. BIOGENA Management Holding took 13.7%, and founders Cornelia Pint and Daniel Taurer hold the remaining 33% through PT26 Holding GmbH.
Sources
- Primary — REPLOID Group AG press release via EQS News, “HEROSAN Launches Crowdfunding Campaign on Invesdor,” September 8, 2026, https://www.eqs-news.com/news/media/herosan-launches-crowdfunding-campaign-on-invesdor/165dd48b-03b7-4ef6-8fc5-70f123c3382a_en
- Secondary — PetsGlobal, “HEROSAN Raises Funding as Insect-Based Pet Nutrition Expands,” September 2026, https://www.petsglobal.com/Infoview/3981/HEROSAN_Raises_Funding_as_Insect-Based_Pet_Nutrition_Expands.html
- Additional — REPLOID Group AG via EQS / FT Markets, “REPLOID accelerates retail push” (ownership structure, August 20, 2026), https://markets.ft.com/data/announce/detail?dockey=600-202608200400DGAP____CORPNEWS_corporate_2386264_en-1
- Additional — PET worldwide, “Biogena acquires a stake in Herosan Petcare,” August 25, 2026
